On March 29, 2021 Allarity Therapeutics A/S ("Allarity" or the "Company") reported that its executive management will host a live webcast on 31 March 2021, at 5:00 p.m. CEST to discuss the company’s full-year and fourth quarter 2020 results and provide a business and financial update (Press release, Allarity Therapeutics, MAR 29, 2021, https://allarity.com/press-release/allarity-therapeutics-invites-investors-for-fy-q4-2020-report-conference-call/ [SID1234577281]). The webcast will follow the publication of Allarity Therapeutic’s FY/Q4 2020 report, also scheduled for release on 31 March 2021.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Interested parties may register for the event and attend it via this link: View Source
Please connect to the web-conference application prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to access the webcast.
Agenda:
General business update by CEO Steve Carchedi
Financial update by CFO Jens Knudsen
Rights Issue
Q&A
Pre-submitted questions will be prioritized for the Q&A. To pre-submit a question, please email it to [email protected], before 2:30 p.m. CEST on 31 March.
Online webcast/conference call:
Attendees are encouraged to pre-register in order to be able to watch the presentation slides using this link:
Attendees who would wish to call in may use the following:
Attendee Dial-in Number: + 1 (312) 248-9348
Attendee Dial-in ID Number: 821771#
Attendee Dial-in Passcode: 7041#
About the Drug Response Predictor – DRP Companion Diagnostic
Allarity uses its drug specific DRP to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, the response rate can be significantly increased. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and prior clinical trial outcomes. DRP is based on messenger RNA from the patient’s biopsies. DRP has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in nearly 40 clinical studies that were examined, including an ongoing, prospective Phase 2 trial. The DRP platform can be used in all cancer types and is patented for more than 70 anti-cancer drugs.